WO2004100942A1 - 体内脂質低下用組成物 - Google Patents
体内脂質低下用組成物 Download PDFInfo
- Publication number
- WO2004100942A1 WO2004100942A1 PCT/JP2004/006538 JP2004006538W WO2004100942A1 WO 2004100942 A1 WO2004100942 A1 WO 2004100942A1 JP 2004006538 W JP2004006538 W JP 2004006538W WO 2004100942 A1 WO2004100942 A1 WO 2004100942A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- psinoid
- composition
- force
- composition according
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/04—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
- G01N27/12—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluid; of a solid body in dependence upon reaction with a fluid, for detecting components in the fluid
Definitions
- the present invention relates to a composition for lowering in-vivo lipids, which contains a force-psinoid compound.
- Patent Document 1 Yazawa et al., In Patent Document 1, clarified that these force-psinoid compounds do not actually exhibit pungency and also have unique functions such as an immune activating action and a body surface temperature increasing action. The present applicants also disclose that the force-psinoid compound has an obesity-suppressing effect (Patent Document 2) and an endurance-improving effect (Patent Document 3).
- Patent Document 1 JP-A-11-246478
- Patent Document 2 JP 2001-26538 A
- Patent Document 3 JP-A-2002-114676
- Non-Patent Document 1 Susumu Yazawa, Journal of Horticultural Society, Vol. 58, pp. 601-607 (1989)
- Non-Patent Document 2 T. Kawada et al., J. Nutr., Vol. 116, pp. 1272-1278 (198 6): Table 2 on page 1274, etc.
- force psinoids and capsaicinoids do not always have the same physiological action due to differences in their structures. Therefore, finding new physiological actions of force psinoids is an interesting issue. is there. In addition, since force psinoids do not have a pungent taste, they can be easily incorporated into foods, medicines, and the like. Therefore, it is significant to confirm the physiological action exhibited by force psinoids.
- an object of the present invention is to clarify a novel physiological action of a force pucinoid compound and apply it to various uses.
- the first of the invention is:
- a composition for lowering body lipids selected from serum cholesterol or hepatic fat which comprises a general formula (1):
- n is an integer of 0 to 10.
- a composition comprising a force-psinoid compound represented by the formula:
- the force psinoids of the present invention improve the arteriosclerosis index by remarkably lowering the total cholesterol in serum, and can be used for prevention or treatment of arteriosclerosis. Therefore, the second aspect of the present invention is:
- composition according to (1) above which improves the arteriosclerosis index by lowering the total serum cholesterol level.
- n 3, 4 or 5
- the compound is 4-hydroxy-3-methoxybenzyl (E) _8-methyl
- the compound is non-6_nonenoate or 4-hydroxy-3-methoxybenzyl 8-methylnonanoate. Therefore, the third and fourth aspects of the present invention are:
- the force-psinoid compound is contained in a capsicum plant that has been eaten in the past, especially when formulated as food or beverage, the force-psinoid compound is necessarily purified and isolated. It can be formulated in the form of a plant or a fruit containing it, in which case a fruit derived from a pepper variety “CH-19 sweet” containing a large amount of the compound can be advantageously used. Therefore, the fifth and sixth aspects of the present invention are: (5) The composition according to any one of (1) to (4) above, wherein the compound is compounded in the form of a plant or fruit containing the compound as a component.
- the power psinoid compound can be suitably blended as an extract from the above-mentioned plant or fruit. Therefore, the seventh and eighth aspects of the present invention,
- composition of the present invention can be formulated as a food, beverage or medicament, and is particularly suitable for those compositions due to the excellent advantage that the power psinoid compound has no pungency. Can be blended. Therefore, the ninth and tenth aspects of the present invention are:
- composition according to any one of (1) to (8) above, which is in the form of a pharmaceutical.
- the power psinoid compound of the present invention can be prepared by purifying and separating from a plant or Z or fruit of a plant belonging to the genus Capsicum (hereinafter referred to as “capsicum”) containing the compound.
- capsicum a plant or Z or fruit of a plant belonging to the genus Capsicum (hereinafter referred to as “capsicum”) containing the compound.
- s can.
- Peppers used for purification are any kind of peppers containing a power pscinoid compound that can be derived from a conventional hot pepper cultivar represented by "Nikko" and "Goshiki”. It can also be used. Among them, "Nikko" and "Goshiki”. It can also be used. Among them, "Nikko" and "Goshiki”.
- CH-19 sweet Manganji, Fushimi Kancho, Shishitou, pepper, and other non-savory varieties of chili peppers contain a large amount of potash psinoid compounds and can be used favorably. it can. Furthermore, the power of using “CH-19 sweet” which is a non-spicy variety is particularly preferable due to its high content of the component.
- CH-19 sweet includes “CH-19 sweet” and progeny related varieties derived from “CH-19 sweet”, and in this specification, “CH-19 sweet” Is used to mean all of these.
- Purification can be carried out by means of solvent extraction well-known to those skilled in the art, various types of chromatography such as silica gel chromatography, high-performance liquid chromatography for preparation, or the like, alone or in appropriate combination.
- solvent extraction well-known to those skilled in the art
- various types of chromatography such as silica gel chromatography, high-performance liquid chromatography for preparation, or the like, alone or in appropriate combination.
- the method described in JP-A-11-246478 can be used.
- the above-mentioned force-psinoid compound can be synthesized, for example, by an ester exchange reaction using a corresponding fatty acid ester and vanillyl alcohol as starting materials as described in JP-A-11-246478. . Alternatively, it may be synthesized by other reaction methods known to those skilled in the art based on the structural formula. Further, the capsinide compound can be easily prepared by a synthesis method using an enzyme.
- a desired force psinoid compound is obtained by utilizing the reverse reaction of a compound such as an ester of a fatty acid and Z or a triglyceride having the fatty acid corresponding to a desired compound with lipase using vanillyl alcohol as a substrate.
- a compound such as an ester of a fatty acid and Z or a triglyceride having the fatty acid corresponding to a desired compound with lipase using vanillyl alcohol as a substrate.
- the details of this method are described in JP-A-2000-312598, and the contents of the above-mentioned published gazettes including this gazette are incorporated herein by reference.
- the capsinoid compound is not particularly purified as a compound and is not isolated or synthesized, for example, a plant and / or a fruit of a pepper variety “CH-19 sweet”, a dried product, a crushed product, or the like. It can be formulated in the form of a crude extract.
- the pepper cultivar “CH-19 sweet” contains almost no pungent or invasive cabsaicinoid, and instead contains a large amount of non-pungent saccharinoid (potassium ester of vanillyl alcohol). Therefore, it does not show the pungency and invasiveness of ordinary pepper, so it can be directly or dried, crushed, crudely extracted, etc.
- plant or fruit form in this specification refers to the plant or Z or fruit as it is, or to a simple physical form such as drying, pulverization or coarse extraction thereof. And Z or forms that have undergone chemical treatment.
- composition of the present invention comprising a force-psinoid compound or a plant containing the same is useful for suppressing the elevation of serum cholesterol and hepatic fat or decreasing their lipid levels in the body.
- Such compositions can be administered orally or parenterally, and are particularly suitable for oral administration because of the lack of pungency of the power pscinoid compounds as described above.
- various formulations can be prepared by adding pharmaceutically acceptable additives according to the administration form.
- pharmaceutically acceptable additives various additives usually used in the field of pharmaceutical preparations can be used, and examples thereof include gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, and hydroxypropynole.
- Methynoresenorelose canoleboxy methinoresenorelose, corn starch, crystallin wax at Mike's mouth, white petrolatum, magnesium aluminate metasilicate, phosphoric anhydride anhydride, resinic acid, citrate, trisodium citrate, hydroxypropylcellulose, sorbito nore, Sorbitan fatty acid ester, polysorbate, sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, polybutylpyrrolidone, magnesium stearate, light anhydrous silicic acid, talc, vegetable oil, benzyl alcohol, gum arabic, propylene glycol , Polyalkylene glycol, cyclodextrin or hydroxypropyl pro building cyclodextrin.
- Dosage forms formulated as a mixture with these additives include, for example, solid preparations such as tablets, capsules, granules, powders and suppositories; or syrups, elixirs or injections And the like, which are common in the pharmaceutical field. It can be prepared by a method. In the case of a liquid preparation, it may be in the form of being dissolved or suspended in water or another appropriate medium at the time of use. In particular, in the case of an injection, it may be dissolved or suspended in a physiological saline solution or a glucose solution as needed, or a buffer or a preservative may be added.
- These preparations can contain the force-psinoid compound of the present invention in a proportion of 11 to 100% by weight, preferably 1080% by weight of the total drug.
- the dosage and number of administrations vary depending on the sex, age, weight, degree of symptoms, the type and range of intended treatment, and the like of the patient. In general, in the case of oral administration, it is preferable to administer 1 to 50 mg / kg per adult per day in several divided doses.
- the potassinoid compound of the present invention can also be arbitrarily blended into various foods, for example, solid, liquid, sol, gel, powder, and granular foods.
- the compounding can be performed by any production method known in the art, for example, solid foods such as chocolate, sports drinks and the like by the method described in JP-A-11-246478.
- Solid foods such as chocolate, sports drinks and the like by the method described in JP-A-11-246478.
- Liquid foods can be easily mixed with retort foods such as azuki porridge.
- the above-mentioned force-psinoid compound can also be used in the form of a food additive.
- the food additive containing the potency psinoid compound of the present invention can be prepared by using a method well known to those skilled in the art, for example, by adding the capsinoid substance together with various excipients such as dextrin, corn starch, lactose, and auxiliary materials such as an emulsifier. It can be manufactured by mixing, granulating or encapsulating. If desired, a preservative or a fragrance may be added.
- the power psidinoid conjugate contained in the food component need not necessarily be sufficiently purified as described above. That is, for example, the above-mentioned non-pungent fixed variety of pepper, "CH-19 sweet" itself (unprocessed product), its dried product (crushed product), or an alcohol or food emulsifier solution such as ethyl acetate and ethanol. And the like, it may be contained as an extract of “CH-19 sweet” with various solvents commonly used for extraction from natural products in the art.
- the power psinoid compound of the present invention can be arbitrarily incorporated into various feeds, for example, solid, liquid, sol, gel, powder, and granular feeds.
- the formulation can be performed by those skilled in the art. It will be readily apparent, for example, that this can be achieved using a method essentially equivalent to the incorporation of the substance in foods, or with appropriate modifications.
- a final concentration of 0.1 mmol of force psicin per lkg of feed was used, and for the 0.1 mmol / kg force psinoid group, a final concentration of 0.1 mmol of force psicinoid per kg of feed was also used.
- a final concentration of 1. Ommol strength psinoid per lkg of feed was added to the control group.
- the force psinoid used was an approximately 2: 1 mixture of 4-hydroxy-3-methoxybenzyl (E) _8-methyl-6_nonenoate: 4-hydroxy-13-methoxybenzyl 8-methylnonanoate.
- Pair feeding was performed for 4 weeks with 6 animals in each group described above.
- the experimental animals were bred in individual cages, weighed once a week during the breeding period, and the daily feed intake was calculated by subtracting the remaining amount from the dose.
- Feces were collected for 3 days before dissection. After breeding, dissection and blood collection were performed, and first, liver, perirenal fat and epididymal fat were excised and weighed. Furthermore, the ratio of each to the body weight was calculated.
- Table 1 shows the progress of breeding
- Table 2 shows the excretion rate of cholesterol in feces for 3 days before dissection
- Table 3 shows the ratio of organ weight to body weight.
- the results are shown as the average soil standard deviation, and statistically, a significance test of p ⁇ 0.05 was performed using ANOVA and Duncan's multiple range test. “*” In the table indicates p ⁇ 0.05.
- Table 1 Breeding process (weight gain, average feed intake)
- T_chol serum total cholesterol
- HDL-chol HDL cholesterol
- the force-psinoid compound of the present invention significantly increased serum total cholesterol. It can be seen that the arteriosclerosis index is significantly improved with the decrease.
- T-lipid total lipids
- Choi cholesterol
- TG tridalicelide
- the compound of the present invention significantly reduces hepatic fat (liver lipid).
- the force-psinoid compound of the present invention significantly lowers the serum total cholesterol level, further improves the arteriosclerosis index, and has not been reported for cabsaicinoid so far. It became clear that the level of hepatic fat was also reduced or suppressed. Therefore, the compounds of the present invention can be very suitably applied to compositions for those uses.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pathology (AREA)
- Electrochemistry (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004238122A AU2004238122B2 (en) | 2003-05-15 | 2004-05-14 | Composition for lowering lipid in body |
EP04733085.7A EP1627634B1 (en) | 2003-05-15 | 2004-05-14 | Use of capsinoids for the treatment of arteriosclerosis |
JP2005506195A JPWO2004100942A1 (ja) | 2003-05-15 | 2004-05-14 | 体内脂質低下用組成物 |
CA2525486A CA2525486C (en) | 2003-05-15 | 2004-05-14 | Composition for lowering the internal lipid |
MXPA05011895A MXPA05011895A (es) | 2003-05-15 | 2004-05-14 | Composiciones para lipidos inferiores en el cuerpo. |
ES04733085.7T ES2441570T3 (es) | 2003-05-15 | 2004-05-14 | Uso de capsinoides para el tratamiento de la arteriosclerosis |
US11/107,745 US7414075B2 (en) | 2003-05-15 | 2005-04-18 | Composition for lowering internal lipid content |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003137317 | 2003-05-15 | ||
JP2003-137317 | 2003-05-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/107,745 Continuation US7414075B2 (en) | 2003-05-15 | 2005-04-18 | Composition for lowering internal lipid content |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004100942A1 true WO2004100942A1 (ja) | 2004-11-25 |
Family
ID=33447253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006538 WO2004100942A1 (ja) | 2003-05-15 | 2004-05-14 | 体内脂質低下用組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7414075B2 (ja) |
EP (1) | EP1627634B1 (ja) |
JP (1) | JPWO2004100942A1 (ja) |
KR (1) | KR20060026408A (ja) |
CN (1) | CN1791400A (ja) |
AU (1) | AU2004238122B2 (ja) |
CA (1) | CA2525486C (ja) |
ES (1) | ES2441570T3 (ja) |
MX (1) | MXPA05011895A (ja) |
PT (1) | PT1627634E (ja) |
WO (1) | WO2004100942A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007145793A (ja) * | 2005-02-01 | 2007-06-14 | Ajinomoto Co Inc | 血行促進外用剤及びこれを含有してなる皮膚毛髪用化粧料及び入浴剤 |
JP2007210969A (ja) * | 2006-02-10 | 2007-08-23 | Ajinomoto Co Inc | コニフェリル誘導体およびその用途 |
WO2008001912A1 (fr) * | 2006-06-29 | 2008-01-03 | Ajinomoto Co., Inc. | Dérivé d'ester benzylique substitué et son utilisation |
JP2008529475A (ja) * | 2005-02-18 | 2008-08-07 | 味の素株式会社 | カプシノイドの脱水縮合による製造方法、カプシノイドの安定化法、並びにカプシノイド組成物 |
JPWO2009014253A1 (ja) * | 2007-07-26 | 2010-10-07 | 味の素株式会社 | カプシノイド化合物を含有する植物体を含む冷凍飲料の製造方法 |
US9399030B2 (en) * | 2005-02-01 | 2016-07-26 | Ajinomoto Co., Inc. | Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same |
WO2019181529A1 (ja) * | 2018-03-23 | 2019-09-26 | 味の素株式会社 | 香気を有するトウガラシ属植物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1790235A4 (en) * | 2004-08-11 | 2010-06-02 | Ajinomoto Kk | METHOD FOR THE PRODUCTION OF CAPSINOID-CONTAINING MICRO-CAPSULES |
KR100756628B1 (ko) * | 2006-02-21 | 2007-09-10 | 김형익 | 이동식 침대 |
WO2007114128A1 (ja) * | 2006-03-31 | 2007-10-11 | Ajinomoto Co., Inc. | カプシノイド含有飲食品の製造方法 |
ES2429288T3 (es) * | 2006-04-24 | 2013-11-14 | Ajinomoto Co., Inc. | Agente para la mejora de la disfagia, y composición farmacéutica o alimenticia que comprende el mismo |
KR100869083B1 (ko) * | 2008-05-20 | 2008-11-17 | (주)새롬바이오 | 다이어트 효과를 갖는 캡사이신의 변화물질을 생산하는 바실러스 서브틸리스 균주 및 캡사이신에 의한 다이어트 효과와 동일한 매운맛이 완화된 캡사이신의 변화물질을 생산하는 방법 |
US10414715B1 (en) * | 2018-10-26 | 2019-09-17 | The United States Of America, As Represented By The Secretary Of Agriculture | Methods for extracting and purifying capsinoids such as capsiate and dihydrocapsiate from capsicum sp. fruit |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0913075A (ja) * | 1995-07-04 | 1997-01-14 | Nisshin Oil Mills Ltd:The | 血中脂質を低減する油脂 |
JPH0923817A (ja) * | 1995-07-07 | 1997-01-28 | Nisshin Oil Mills Ltd:The | 油脂含有飲食物 |
JPH0930962A (ja) * | 1995-07-21 | 1997-02-04 | Nisshin Oil Mills Ltd:The | 医療用油脂含有組成物 |
JPH11246478A (ja) | 1998-03-04 | 1999-09-14 | Morinaga & Co Ltd | エステル結合を有する新規なカプサイシノイド様物質 |
JP2001026538A (ja) * | 1999-07-13 | 2001-01-30 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する食品及び医薬組成物 |
WO2002017906A1 (en) * | 2000-08-30 | 2002-03-07 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
JP2002114676A (ja) | 2000-10-06 | 2002-04-16 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する持久力向上用組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6070339A (en) * | 1998-10-23 | 2000-06-06 | Westinghouse Air Brake Company | Membrane air dryer with scheme to reduce air lost as sweep air |
-
2004
- 2004-05-14 JP JP2005506195A patent/JPWO2004100942A1/ja active Pending
- 2004-05-14 MX MXPA05011895A patent/MXPA05011895A/es active IP Right Grant
- 2004-05-14 EP EP04733085.7A patent/EP1627634B1/en not_active Expired - Lifetime
- 2004-05-14 PT PT47330857T patent/PT1627634E/pt unknown
- 2004-05-14 AU AU2004238122A patent/AU2004238122B2/en not_active Ceased
- 2004-05-14 KR KR1020057021643A patent/KR20060026408A/ko not_active Application Discontinuation
- 2004-05-14 ES ES04733085.7T patent/ES2441570T3/es not_active Expired - Lifetime
- 2004-05-14 CA CA2525486A patent/CA2525486C/en not_active Expired - Fee Related
- 2004-05-14 CN CNA2004800133525A patent/CN1791400A/zh active Pending
- 2004-05-14 WO PCT/JP2004/006538 patent/WO2004100942A1/ja active IP Right Grant
-
2005
- 2005-04-18 US US11/107,745 patent/US7414075B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0913075A (ja) * | 1995-07-04 | 1997-01-14 | Nisshin Oil Mills Ltd:The | 血中脂質を低減する油脂 |
JPH0923817A (ja) * | 1995-07-07 | 1997-01-28 | Nisshin Oil Mills Ltd:The | 油脂含有飲食物 |
JPH0930962A (ja) * | 1995-07-21 | 1997-02-04 | Nisshin Oil Mills Ltd:The | 医療用油脂含有組成物 |
JPH11246478A (ja) | 1998-03-04 | 1999-09-14 | Morinaga & Co Ltd | エステル結合を有する新規なカプサイシノイド様物質 |
EP1069105A1 (en) | 1998-03-04 | 2001-01-17 | MORINAGA & CO., LTD. | Novel capsaicinoide-like substances having ester bond |
JP2001026538A (ja) * | 1999-07-13 | 2001-01-30 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する食品及び医薬組成物 |
WO2002017906A1 (en) * | 2000-08-30 | 2002-03-07 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
JP2002114676A (ja) | 2000-10-06 | 2002-04-16 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する持久力向上用組成物 |
Non-Patent Citations (11)
Title |
---|
"Database", accession no. 002-458891 |
IWA ET AL., PROCEEDINGS OF THE JAPAN ACADEMY, SERIES B: PHYSICAL AND BIOLOGICAL SCIENCES, vol. 79, no. 7, September 2003 (2003-09-01), pages 207 - 212 |
KOBATA K ET AL., JOURNAL OF NATURAL PRODUCTS 199902 US, vol. 62, no. 2, February 1999 (1999-02-01), pages 335 - 336 |
NANZANDO IGAKU DAIJITEN (GOKABAN), 16 January 1998 (1998-01-16), pages 660, XP002982794 * |
NEGULESCO J A ET AL., ATHEROSCLEROSIS, vol. 64, no. 2-3, April 1987 (1987-04-01), pages 85 - 90 |
OHNUKI K ET AL., BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, TOKYO, JAPAN, vol. 65, no. 12, 1 December 2001 (2001-12-01), pages 2735 - 2740 |
SAMBAIAH K ET AL., DATABASE BIOSIS [ONLINE] BIOSCIENCES INFORMATION SERVICE, 1978 |
SAMBAIAH K ET AL., INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 18, 1 August 1980 (1980-08-01), pages 898,899 |
See also references of EP1627634A4 * |
SRINIVASAN K: "Food Research International", vol. 38, 1 January 2005, ELSEVIER APPLIED SCIENCE, pages: 77 - 86 |
SRINIVASAN M R ET AL., DATABASE BIOSIS [ONLINE] BIOSCIENCES INFORMATION SERVICE, 1979 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007145793A (ja) * | 2005-02-01 | 2007-06-14 | Ajinomoto Co Inc | 血行促進外用剤及びこれを含有してなる皮膚毛髪用化粧料及び入浴剤 |
US9399030B2 (en) * | 2005-02-01 | 2016-07-26 | Ajinomoto Co., Inc. | Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same |
JP2008529475A (ja) * | 2005-02-18 | 2008-08-07 | 味の素株式会社 | カプシノイドの脱水縮合による製造方法、カプシノイドの安定化法、並びにカプシノイド組成物 |
JP2007210969A (ja) * | 2006-02-10 | 2007-08-23 | Ajinomoto Co Inc | コニフェリル誘導体およびその用途 |
WO2008001912A1 (fr) * | 2006-06-29 | 2008-01-03 | Ajinomoto Co., Inc. | Dérivé d'ester benzylique substitué et son utilisation |
US7981460B2 (en) | 2006-06-29 | 2011-07-19 | Ajinomoto Co., Inc. | Substituted benzyl ester derivative and use thereof |
JPWO2009014253A1 (ja) * | 2007-07-26 | 2010-10-07 | 味の素株式会社 | カプシノイド化合物を含有する植物体を含む冷凍飲料の製造方法 |
WO2019181529A1 (ja) * | 2018-03-23 | 2019-09-26 | 味の素株式会社 | 香気を有するトウガラシ属植物 |
Also Published As
Publication number | Publication date |
---|---|
AU2004238122B2 (en) | 2007-03-08 |
ES2441570T3 (es) | 2014-02-05 |
CN1791400A (zh) | 2006-06-21 |
KR20060026408A (ko) | 2006-03-23 |
MXPA05011895A (es) | 2006-02-17 |
EP1627634A4 (en) | 2009-08-19 |
EP1627634B1 (en) | 2013-10-16 |
CA2525486C (en) | 2012-09-18 |
PT1627634E (pt) | 2013-10-24 |
EP1627634A1 (en) | 2006-02-22 |
CA2525486A1 (en) | 2004-11-25 |
US20050239883A1 (en) | 2005-10-27 |
US7414075B2 (en) | 2008-08-19 |
AU2004238122A1 (en) | 2004-11-25 |
JPWO2004100942A1 (ja) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7414075B2 (en) | Composition for lowering internal lipid content | |
EP1069105B1 (en) | Capsaicinoide-like substances having ester bond | |
US9492424B2 (en) | Muscle atrophy inhibitor | |
WO1997047209A1 (fr) | Amelioration du metabolisme lipidique | |
JP6335508B2 (ja) | 成長ホルモン分泌促進剤 | |
TWI830917B (zh) | 源自植物之間苯二酚性脂質之用於調製肝炎症狀改善用組成物的用途 | |
US20080213413A1 (en) | Compositions containing capsinoids | |
JP6830976B2 (ja) | マイクロrnaの発現亢進剤及びマイクロrna発現亢進用飲食品 | |
JP4560864B2 (ja) | 新規なカプサイシノイド様物質を含有する鎮痛剤、食品及び飼料 | |
WO2005027949A1 (ja) | ウコン含有組成物 | |
KR20140045161A (ko) | 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물 | |
JP2002114676A (ja) | 新規なカプサイシノイド様物質を含有する持久力向上用組成物 | |
JP4666736B2 (ja) | 高血圧症予防・改善・治療剤 | |
JP4520602B2 (ja) | 高血圧症予防・治療剤 | |
JP2002316940A (ja) | 大腸癌予防剤 | |
JP2003342172A (ja) | カプサイシノイド様物質を含有する糖尿病血糖値低下組成物およびカプサイシノイド様物質の糖尿病血糖値低下剤としての使用 | |
JP2023140651A (ja) | 便通改善用組成物、便通改善用組成物の製造方法、及び便通を改善する方法 | |
JP2001122778A (ja) | 油脂組成物 | |
JP2020533394A (ja) | 体脂肪減少補助剤およびベータグルカンを有効成分とする肥満の予防または治療用組成物 | |
JP2003321361A (ja) | カプサイシノイド様物質を含有する抗掻痒組成物およびカプサイシノイド様物質の抗掻痒剤としての使用 | |
JP2006104156A (ja) | 血圧降下用組成物 | |
JP2009256220A (ja) | リポキシゲナーゼ完全欠失大豆とキラヤ抽出物とユッカ抽出物とを含む組成物とその利用 | |
JP2003286182A (ja) | IgE産生抑制剤 | |
JP2009256221A (ja) | リポキシゲナーゼ完全欠失低脂質大豆とキラヤ抽出物とユッカ抽出物とを含む組成物とその利用 | |
JP2015017043A (ja) | コレステロール吸収抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2005506195 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11107745 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004238122 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004238122 Country of ref document: AU Date of ref document: 20040514 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004238122 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004733085 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/011895 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2525486 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057021643 Country of ref document: KR Ref document number: 3008/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048133525 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004733085 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057021643 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004238122 Country of ref document: AU |